

A 1 acid sequences of the respective E1 or E2 proteins as shown in the sequence listing.--

Page 38, delete the paragraph spanning lines 31-34, and insert the following therefor:

A 2 --Figures 35A-1 to 35A-8: Antibody levels to the different HCV antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curves with the open squares.--

Page 39, delete the paragraph spanning lines 1-4, and insert the following therefor: ]

--Figures 35B-1 to 35B-8: Antibody levels to the different HCV antigens (NS4, NS5, E1 and E2) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curve with the open squares.--

[Page 39, delete the paragraph spanning lines 6 and 7, and insert the following  
therefor:]

--Figures 36A and 36 B: Average E1 antibody (E1Ab) and E2 antibody  
(E2Ab) levels in the LTR and NR groups.—

[Page 39, delete the paragraph spanning lines 8 and 9, and insert the following  
therefor:]

--Figures 37A-D: Averages E1 antibody (E1Ab) levels for non-  
responders (NR) and long term responders  
(LTR) for type 1b and type 3a.--

### IN THE ABSTRACT

Insert the attached Abstract after the claims pages.

### IN THE DRAWINGS

Insert the attached formal drawings for the originally-filed drawings.

### IN THE CLAIMS

Cancel claims 1-48, without prejudice.

Add the following claims.

A<sup>2</sup>  
MAB7  
--49/ (new) An isolated antibody selected from the group consisting of an E1  
specific monoclonal antibody, an E2 specific monoclonal antibody and an E1/E2 specific  
monoclonal antibody.